Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Martin Torriani, M.D.

Co-Author

This page shows the publications co-authored by Martin Torriani and Takara Stanley.
Connection Strength

2.058
  1. Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease. Clin Infect Dis. 2021 08 16; 73(4):621-630.
    View in: PubMed
    Score: 0.245
  2. Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease. J Clin Endocrinol Metab. 2021 01 23; 106(2):e520-e533.
    View in: PubMed
    Score: 0.235
  3. Effect of recombinant human growth hormone on liver fat content in young adults with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf). 2021 02; 94(2):183-192.
    View in: PubMed
    Score: 0.231
  4. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019 12; 6(12):e821-e830.
    View in: PubMed
    Score: 0.215
  5. Effects of Pitavastatin on Insulin Sensitivity and Liver Fat: A Randomized Clinical Trial. J Clin Endocrinol Metab. 2018 11 01; 103(11):4176-4186.
    View in: PubMed
    Score: 0.202
  6. Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation. Growth Horm IGF Res. 2017 12; 37:1-6.
    View in: PubMed
    Score: 0.187
  7. Visceral and subcutaneous adipose tissue FDG uptake by PET/CT in metabolically healthy obese subjects. Obesity (Silver Spring). 2015 Feb; 23(2):286-9.
    View in: PubMed
    Score: 0.154
  8. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014 Jul 23-30; 312(4):380-9.
    View in: PubMed
    Score: 0.149
  9. Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease. Clin Infect Dis. 2021 06 15; 72(12):2087-2094.
    View in: PubMed
    Score: 0.060
  10. Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Sci Rep. 2021 05 18; 11(1):10485.
    View in: PubMed
    Score: 0.060
  11. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight. 2020 08 20; 5(16).
    View in: PubMed
    Score: 0.057
  12. Comparison of visceral fat measurement by dual-energy X-ray absorptiometry to computed tomography in HIV and non-HIV. Nutr Diabetes. 2019 02 25; 9(1):6.
    View in: PubMed
    Score: 0.052
  13. Randomized, Placebo-Controlled Trial to Evaluate Effects of Eplerenone on Metabolic and Inflammatory Indices in HIV. J Clin Endocrinol Metab. 2018 06 01; 103(6):2376-2384.
    View in: PubMed
    Score: 0.049
  14. Metabolic Effects of Long-Term Reduction in Free Fatty Acids With Acipimox in Obesity: A Randomized Trial. J Clin Endocrinol Metab. 2016 Mar; 101(3):1123-33.
    View in: PubMed
    Score: 0.041
  15. FNDC5 relates to skeletal muscle IGF-I and mitochondrial function and gene expression in obese men with reduced growth hormone. Growth Horm IGF Res. 2016 Feb; 26:36-41.
    View in: PubMed
    Score: 0.041
  16. RAAS Activation Is Associated With Visceral Adiposity and Insulin Resistance Among HIV-infected Patients. J Clin Endocrinol Metab. 2015 Aug; 100(8):2873-82.
    View in: PubMed
    Score: 0.040
  17. Effects of recombinant human growth hormone (rhGH) administration on body composition and cardiovascular risk factors in obese adolescent girls. Int J Pediatr Endocrinol. 2014; 2014(1):22.
    View in: PubMed
    Score: 0.038
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.